Bavarian Nordic Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma

NEXT STORY
Cybin Inc. (NEO: CYBN) Looking to Solve Long-Standing Problem with MDD Treatment
PREV STORY
Report from the Extraordinary General Meeting of Immunicum AB (publ) on December 18, 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

author_avatar
NASDAQ Market News

Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome

author_avatar
NASDAQ Market News

Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results

Conference Call Scheduled November 12, 2018 at 4:30 p.m. ET BERKELEY HEIGHTS, N.J., Nov. ...

author_avatar
NASDAQ Market News